ライフサイエンスコーパス: inosine monophosphate

1 functional reaction toward the production of inosine monophosphate.

2 ps in the formation of the first purine base inosine monophosphate.

3 of Ppat, a key enzyme for the production of inosine monophosphate, a central metabolic intermediate

4 nce of several umami (uridine monophosphate, inosine monophosphate, adenosine, and guanosine) and kok

5 deregulated serum acylcarnitines, including inosine monophosphate and adenosine monophosphate (purin

6 nucleotide cycle (PNC) between adenosine and inosine monophosphate and adenylosuccinate, which consum

7 le in the formation of the key intermediates inosine monophosphate and AMP involved in the synthesis

8 As a reduction in succinate, inosine monophosphate and choline during storage were fo

9 nd valine were increased, whereas succinate, inosine monophosphate and choline were decreased over th

10 alanine, methionine, fumaric acid, inosine, inosine monophosphate, creatine, betaine, carnosine and

11 carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase (ATIC) and thereby

12 le carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase (ATIC) is responsib

13 ide ribonucleotide (AICAR) transformylase/5'-inosine monophosphate cyclohydrolase (ATIC), a bifunctio

14 carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase (ATIC), SHMT1, and

15 the bifunctional enzyme AICAR transformylase/inosine monophosphate cyclohydrolase (ATIC).

16 carboxamide ribonucleotide formyltransferase/inosine monophosphate cyclohydrolase (ATIC).

17 The inosine monophosphate cyclohydrolase (IMPCH) component (

18 arboxamide ribonucleotide transformylase and inosine monophosphate cyclohydrolase activities, and exi

19 -4-carboxamide ribonucleotide transformylase/inosine monophosphate cyclohydrolase, Steps 9 and 10), w

20 cophenolic acid (MPA), a potent inhibitor of inosine monophosphate dehydrogenase (IMPD), derived from

21 nosine monophosphate (GMP)-producing enzymes inosine monophosphate dehydrogenase (IMPDH) and guanosin

22 Inosine monophosphate dehydrogenase (IMPDH) catalyzes th

23 Inosine monophosphate dehydrogenase (IMPDH) controls a k

24 Interindividual variation in inosine monophosphate dehydrogenase (IMPDH) enzyme activ

25 The guanine nucleotide biosynthetic enzyme inosine monophosphate dehydrogenase (IMPDH) forms octame

26 e cloned and characterized the gene encoding inosine monophosphate dehydrogenase (IMPDH) from Arabido

27 e cloned and characterized the gene encoding inosine monophosphate dehydrogenase (IMPDH) from Pyrococ

28 MPA is a potent inosine monophosphate dehydrogenase (IMPDH) inhibitor bu

29 ted that mycophenolic acid (MPA), a specific inosine monophosphate dehydrogenase (IMPDH) inhibitor th

30 Inosine monophosphate dehydrogenase (IMPDH) is a key reg

31 Inosine monophosphate dehydrogenase (IMPDH) is a rate-li

32 Inosine monophosphate dehydrogenase (IMPDH) is a target

33 The enzyme inosine monophosphate dehydrogenase (IMPDH) is responsib

34 Inosine monophosphate dehydrogenase (IMPDH) is the rate-

35 Inosine monophosphate dehydrogenase (IMPDH) mediates the

36 uanine nucleotide negatively regulates yeast inosine monophosphate dehydrogenase (IMPDH) mRNA synthes

37 guanine nucleotide pools after inhibition of inosine monophosphate dehydrogenase (IMPDH) potently inh

38 The inosine monophosphate dehydrogenase (IMPDH) protein GuaB

39 is carried out by two isoforms of the enzyme inosine monophosphate dehydrogenase (IMPDH) that are cat

40 e-MAD, was found to be a potent inhibitor of inosine monophosphate dehydrogenase (IMPDH) type II (Ki

41 competitive inhibitor, mycophenolic acid, to inosine monophosphate dehydrogenase (IMPDH) were measure

42 Inosine monophosphate dehydrogenase (IMPDH), a key enzym

43 We recently reported that Inosine Monophosphate Dehydrogenase (IMPDH), a rate-limi

44 MPA selectively inhibits inosine monophosphate dehydrogenase (IMPDH), a rate-limi

45 Inosine monophosphate dehydrogenase (IMPDH), a rate-limi

46 dinucleotide (BAD) are potent inhibitors of inosine monophosphate dehydrogenase (IMPDH), the corresp

47 tem and hypoxanthine require the activity of inosine monophosphate dehydrogenase (IMPDH), the rate-li

48 reductase-thymidylate synthase (DHFR-TS) and inosine monophosphate dehydrogenase (IMPDH).

49 ave been prepared as potential inhibitors of inosine monophosphate dehydrogenase (IMPDH).

50 synthesized as potential inhibitor of human inosine monophosphate dehydrogenase (IMPDH).

51 nockdown of one of the two known isoforms of inosine monophosphate dehydrogenase (IMPDH-1) is suffici

52 ose of this study was to investigate retinal inosine monophosphate dehydrogenase 1 (IMPDH1) transcrip

53 strated a 6-fold reduction in one candidate, inosine monophosphate dehydrogenase 1 (IMPDH1; EC 1.1.1.

54 Antibodies to inosine monophosphate dehydrogenase 2 (IMPDH2) and cytid

55 Here, we identify inosine monophosphate dehydrogenase 2 (IMPDH2) as a cont

56 Mechanistically, targeting inosine monophosphate dehydrogenase 2 (IMPDH2) reduces g

57 ANKRD9 facilitates degradation of inosine monophosphate dehydrogenase 2 (IMPDH2), the rate

58 metabolism enzymes, including rate-limiting inosine monophosphate dehydrogenase 2 (IMPDH2), which wa

59 glioblastoma through indirect inhibition of inosine monophosphate dehydrogenase 2 (IMPDH2).

60 Inhibitors of the enzyme inosine monophosphate dehydrogenase augmented both IFN-d

61 quantitation of cancer-associated proteins (inosine monophosphate dehydrogenase II, vascular endothe

62 ariant induced collateral sensitivity to the inosine monophosphate dehydrogenase inhibitor mizoribine

63 s in the region of the phthalide ring of the inosine monophosphate dehydrogenase inhibitor mycophenol

64 erimepodib (MMPD) is an orally administered, inosine monophosphate dehydrogenase inhibitor that has s

65 amycin [mTOR]) and mycophenolate mofetil (an inosine monophosphate dehydrogenase inhibitor).

66 y)adenine)], alone or in combination with an inosine monophosphate dehydrogenase inhibitor, reduced H

67 esistance in relapsed B-ALL and suggest that inosine monophosphate dehydrogenase inhibitors, includin

68 BAD inhibits inosine monophosphate dehydrogenase type I (IC50 = 0.78

69 s to determine the frequency and spectrum of inosine monophosphate dehydrogenase type I (IMPDH1) muta

70 ere-associated protein E (Cenpe), Gpr49, and inosine monophosphate dehydrogenase type II] with previo

71 of pharmaceutical interest: p38 MAP kinase, inosine monophosphate dehydrogenase, and HIV protease.

72 itro inhibition of the pharmacologic target, inosine monophosphate dehydrogenase, is dependent on fre

73 henolic acid (MPA), a selective inhibitor of inosine monophosphate dehydrogenase, is the active agent

74 rs the parasite susceptible to inhibition of inosine monophosphate dehydrogenase, the rate-limiting e

75 and it concurrently blocked the activity of inosine monophosphate dehydrogenase, the rate-limiting e

76 it lymphocyte proliferation by inhibition of inosine monophosphate dehydrogenase.

77 a potent and specific inhibitor of mammalian inosine-monophosphate dehydrogenases (IMPDH); most micro

78 Inosine monophosphate enhanced taste cell responses to L

79 this goal, we report the use of 5'-O-(1-thio)inosine monophosphate (IMP alphaS) in a nucleotide analo

80 at PfISN1 catalyzes the dephosphorylation of inosine monophosphate (IMP) and is allosterically activa

81 zwf- cells showed that the concentrations of inosine monophosphate (IMP) and uridine monophosphate (U

82 Although inosine monophosphate (IMP) cannot be detected in crude

83 oxamide ribonucleotide (FAICAR) synthase and inosine monophosphate (IMP) cyclohydrolase activity.

84 Inosine monophosphate (IMP) dehydrogenase 2 (IMPDH2) is

85 nstrate that itaconate inhibits aldolase and inosine monophosphate (IMP) dehydrogenase in a concentra

86 Inosine monophosphate (IMP) is the intracellular precurs

87 al enzyme that catalyzes steps 2, 3 and 5 of inosine monophosphate (IMP) synthesis.

88 e (i(6)A), are sequentially metabolized into inosine monophosphate (IMP) to mitigate their intrinsic

89 The enzyme catalyzes the oxidation of inosine monophosphate (IMP) to xanthosine monophosphate

90 ) and its enzymatic activity (EC) generating inosine monophosphate (IMP) were identified with transcr

91 amic properties of binding of the substrate, inosine monophosphate (IMP), and the uncompetitive inhib

92 sphate (ADP), adenosine monophosphate (AMP), inosine monophosphate (IMP), inosine (Ino) and hypoxanth

93 sphate (ADP), adenosine monophosphate (AMP), inosine monophosphate (IMP), inosine, and hypoxanthine.

94 res 10 enzymatic steps for the production of inosine monophosphate (IMP).

95 te (MSG), monopotassium glutamate (MPG), and inosine monophosphate (IMP)] taste as well.

96 Incorporation of inosine monophosphate inhibited next nucleotide addition

97 ediate pools and a perturbed partitioning of inosine monophosphate into AMP and GMP.

98 highly elevated adenosine monophosphate and inosine monophosphate levels, the depletion of essential

99 significantly rescued either by addition of inosine monophosphate or a nucleoside mixture or by stab

100 deaminase (ADA), adenosine kinase (AK), and inosine monophosphate-specific cytosolic 5'-nucleotidase

101 The highest concentration of inosine monophosphate was achieved in freshly prepared g

102 al steps from phosphoribosylpyrophosphate to inosine monophosphate were recently shown to associate i

103 cleosides and nucleotides (e.g., inosine and inosine monophosphate) were also found to be transformed